These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9818151

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV, Kim UT, Liang J, Cordova B, Klabe RM, Garber S, Bacheler LT, Lam GN, Wright MR, Logue KA, Erickson-Viitanen S, Ko SS, Trainor GL.
    J Med Chem; 1998 Jun 18; 41(13):2411-23. PubMed ID: 9632373
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK, Ala P, Woerner FJ, Chang CH, Garber SS, Anton ED, Bacheler LT.
    J Med Chem; 1997 Jan 17; 40(2):181-91. PubMed ID: 9003516
    [Abstract] [Full Text] [Related]

  • 6. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD, Johnson BL, Wang H, Erickson-Viitanen S, Klabe RM, Bacheler L, Cordova BC, Chang CH.
    Bioorg Med Chem Lett; 1998 Apr 07; 8(7):715-20. PubMed ID: 9871528
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V, Burello E, Miertus S.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5492-501. PubMed ID: 16054372
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M, Kaltenbach RF, Nugiel DA, McHugh RJ, Jadhav PK, Bacheler LT, Cordova BC, Klabe RM, Erickson-Viitanen S, Garber S, Reid C, Seitz SP.
    Bioorg Med Chem Lett; 1998 May 05; 8(9):1077-82. PubMed ID: 9871711
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
    Acc Chem Res; 2008 Jan 05; 41(1):78-86. PubMed ID: 17722874
    [Abstract] [Full Text] [Related]

  • 17. Non-peptidic HIV protease inhibitors.
    Chrusciel RA, Strohbach JW.
    Curr Top Med Chem; 2004 Jan 05; 4(10):1097-114. PubMed ID: 15193141
    [Abstract] [Full Text] [Related]

  • 18. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S, Meek JL.
    Biochemistry; 1998 Jun 16; 37(24):8735-42. PubMed ID: 9628735
    [Abstract] [Full Text] [Related]

  • 19. Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
    Kaltenbach RF, Klabe RM, Cordova BC, Seitz SP.
    Bioorg Med Chem Lett; 1999 Aug 02; 9(15):2259-62. PubMed ID: 10465557
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.